factors will ensure open dialog. New information supports a shift from the paradigm of discon tinuing all RMD medications except prednisone, since pregnancy-compatible steroid-sparing disease-modifying antirheumatic drugs and biologic agents pose fewer short-and long-term risks to mother and infant. With adequate planning, treatment, and monitoring, most women with RMD can have successful pregnancies. Recent data indicate compatibility of many rheumatology medications both with lactation and